Mounjaro

Product

Heard on podcasts recently

Mounjaro is Eli Lilly’s prescription injectable medicine containing tirzepatide, a dual GIP and GLP-1 receptor agonist. It is used with diet and exercise to improve blood-sugar control in people with type 2 diabetes; the podcast references primarily describe its strong diabetes-treatment sales and demand, while distinguishing it from Lilly’s obesity brand, Zepbound.

Rank this week

—
Not in this week’s list

Share of the conversation

—

Reach this week

—

Tone this week

—

Not enough signal yet (fewer than 3 episodes scored).

Share of the conversation

Mentions of Mounjaro per 1,000 mentions of anything, 7-day rolling, all podcasts.

0.0‰0.2‰0.4‰0.6‰0.8‰Aug 15Sep 6Sep 29Oct 21Nov 12
Show the data
DayShare (7-day)Mentions
Aug 150.60‰1
Aug 160.72‰1
Aug 210.08‰1
Aug 290.01‰1
Sep 30.03‰2
Sep 80.03‰1
Sep 130.04‰3
Sep 200.02‰2
Sep 210.03‰1
Sep 230.04‰1
Sep 250.04‰1
Oct 180.02‰2
Oct 200.03‰1
Oct 210.03‰1
Oct 250.02‰1
Oct 270.02‰1
Oct 290.04‰3
Oct 300.05‰1
Oct 310.07‰2
Nov 10.07‰1
Nov 80.02‰2
Nov 90.02‰1

Who is saying what about Mounjaro

Verified quotes from the last 90 days: who made the most claims, and which way they leaned.

Discussed alongside

Names that come up in the same conversations as Mounjaro.

See 5 more with Trends Pro

Embed this

Paste this on your site to show Mounjaro's current trend:

<iframe src="https://podlume.ai/embed/e/mounjaro" width="360" height="220" style="border:0" loading="lazy" title="Mounjaro on PodLume Trends"></iframe>